<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">Darunavir is an inhibitor of protease dimerization and catalytic activity of HIV-1 [
 <xref ref-type="bibr" rid="CR74">74</xref>, 
 <xref ref-type="bibr" rid="CR75">75</xref>]. It can selectively inhibit the cleavage of HIV encoded gag-pol precursor protein in virus infected cells, thus blocking the formation of mature infectious virus particles [
 <xref ref-type="bibr" rid="CR76">76</xref>, 
 <xref ref-type="bibr" rid="CR77">77</xref>]. Clinically, darunavir is mainly used as a drug for AIDS. On February 4, 2020, it was announced that darunavir could significantly inhibit the replication of the virus at concentration of 300 μmol/L [
 <xref ref-type="bibr" rid="CR32">32</xref>, 
 <xref ref-type="bibr" rid="CR54">54</xref>].
</p>
